GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Trial Details

NCT ID

NCT05913388

Phase

PHASE2

Sponsor

Providence Health & Services

Status

RECRUITING

Cancer Type

Melanoma

Interventions

• GB1211
• Pembrolizumab
• Placebo

Locations (sample)

• Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

• Patients with unresectable or metastatic melanoma including unknown primary or mucosal melanomas. Histological confirmation of melanoma will be req…
• Patients who have received anti-PD1 or anti-PD-L1 in the past are eligible if it has been at least 6 months since the last anti-PD-1 or PD-L1 dose,…
• Patients must be ≥ 18 years of age.
• ECOG performance status of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.